News | August 10, 2022
Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Subscribe To Our Newsletter & Stay Updated
